magnesium isoglycyrrhizinate + diammonium glycyrrhizinate

This is a **combination drug** consisting of magnesium isoglycyrrhizinate and diammonium glycyrrhizinate, both of which are derivatives of glycyrrhizic acid, a bioactive component from licorice (*Glycyrrhiza glabra*). Both agents are known for their **hepatoprotective**, anti-inflammatory, and antioxidant effects. - **Magnesium isoglycyrrhizinate** primarily acts by stabilizing hepatocyte membranes, reducing oxidative stress (notably through glutathione metabolism), inhibiting reactive oxygen species, and modulating immune and inflammatory signaling (including the IL-6 pathway)[1][2][3][4][5]. It is particularly prominent in preventing and treating drug-induced liver injury (DILI) and acute inflammatory liver diseases. - **Diammonium glycyrrhizinate** exhibits hepatoprotective properties via anti-inflammatory and antiviral actions, and upregulation of enzymes such as 11β-HSD1, increasing active glucocorticoids within cells[1]. It is favored in the management of non-alcoholic fatty liver disease (NAFLD) and viral hepatitis due to its immunomodulatory and metabolic effects[1][5]. - **Combined use** of these two agents is designed to leverage their overlapping and complementary liver-protective mechanisms, providing broad protection in diverse liver ailments including DILI, NAFLD, and viral hepatitis[1][5].

Other names

magnesium isoglycyrrhizinate and diammonium glycyrrhizinate combination